PROGRAM CHAIR
Julia K. Rotow, MD
Medical Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA
PROGRAM OVERVIEW
This enduring activity is designed for academic and community medical oncologists, pathologists, nurse practitioners, physician assistants, and pharmacists who care for patients with non-small cell lung cancer (NSCLC). We aim to increase the target healthcare provider’s ability to: describe the role of TROP2 in the clinicopathophysiology of NSCLC and its role in treatment as a targetable protein; assess the clinical trials data for TROP2-targeted therapy, in the second-line, for those patients with relapsed/refractory NSCLC; and identify strategies for managing adverse events, patient and treatment selection that include TROP2-directed antibody-drug conjugates.
TARGET AUDIENCE
This enduring activity is intended for academic and community medical oncologists, pathologists, nurse practitioners, physician assistants, and pharmacists who care for patients with non-small cell lung cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the role of TROP2 in the clinicopathophysiology of NSCLC and its role in treatment as a targetable protein
- Assess the clinical trials data for TROP2-targeted therapy, in the second-line, for those patients with relapsed/refractory NSCLC
- Identify strategies for managing adverse events, patient and treatment selection that include TROP2-directed ADCs
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Julia K. Rotow, MD | Discloses that she has received consulting fees from AstraZeneca, AbbVie, Gritstone bio, Lilly, Takeda, Sanofi Genzyme, Genentech, Guardant Health, BioAtla, Summit Therapeutics, and G1 Therapeutics; she has also been contracted for research with Bicycle Therapeutics, EpimAb Biotherapeutics, Enliven Therapeutics, Daiichi Sankyo, ORIC, BioAtla, AstraZeneca, AbbVie, Blueprint Medicines, RedCloudBio, Loxo Oncology, and Duality Biologics; and has received honoraria from AstraZeneca. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they partner have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Teresa L. Keating, MSN, RN, WHNP, UMA/CCM – LNP, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: August 01, 2023
EXPIRATION DATE: August 01, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
